Bacoside A

Synonyms: 假马齿苋皂素 A
Bacoside A 是一种源自 Bacopa monniera 的口服有效且具有血脑屏障通透性的三萜皂苷,能够调节 ATP 酶、AChE、CaMK2A 及 iNOS 的活性,并通过维持离子平衡、清除活性氧、稳定细胞膜以及调控 NF-κB 和凋亡相关蛋白表达而发挥显著的抗氧化、抗炎和抗凋亡作用,同时可对抗吗啡诱导的 Na+/K+-ATPase、Ca2+-ATPase 和 Mg2+-ATPase 活性降低,提高线粒体膜电位并降低细胞内活性氧水平,还能特异性结合钙/钙调蛋白依赖性蛋白激酶 IIA 触发内质网钙释放,对胶质母细胞瘤细胞表现出非凋亡性细胞毒性并保护正常神经细胞免受应激损伤,可用于帕金森病及多形性胶质母细胞瘤的研究。
产品编号: MS-S57552 CAS No.: 11028-00-5 分子式: C41H68O13 分子量: 768.97
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Bacoside A 是一种源自 Bacopa monniera 的口服有效且具有血脑屏障通透性的三萜皂苷,能够调节 ATP 酶、AChE、CaMK2A 及 iNOS 的活性,并通过维持离子平衡、清除活性氧、稳定细胞膜以及调控 NF-κB 和凋亡相关蛋白表达而发挥显著的抗氧化、抗炎和抗凋亡作用,同时可对抗吗啡诱导的 Na+/K+-ATPase、Ca2+-ATPase 和 Mg2+-ATPase 活性降低,提高线粒体膜电位并降低细胞内活性氧水平,还能特异性结合钙/钙调蛋白依赖性蛋白激酶 IIA 触发内质网钙释放,对胶质母细胞瘤细胞表现出非凋亡性细胞毒性并保护正常神经细胞免受应激损伤,可用于帕金森病及多形性胶质母细胞瘤的研究。

生物实验数据

生物活性 Bacoside A is an orally effective, blood-brain barrier-permeable triterpenoid saponin derived from Bacopa monniera that modulates the activities of ATPases, AChE, CaMK2A, and iNOS, exerts significant antioxidant, anti-inflammatory, and anti-apoptotic effects by maintaining ion homeostasis, scavenging reactive oxygen species, stabilizing cell membranes, and regulating NF-κB and apoptosis-related protein expression, counteracts morphine-induced reductions in Na+/K+-ATPase, Ca2+-ATPase, and Mg2+-ATPase activities, increases mitochondrial membrane potential, decreases intracellular reactive oxygen species levels, specifically binds calcium/calmodulin-dependent protein kinase IIA to trigger endoplasmic reticulum calcium release, exhibits non-apoptotic cytotoxicity against glioblastoma cells while protecting normal neuronal cells from stress-induced damage, and can be used for research on Parkinson's disease and glioblastoma multiforme.
IC50 & Target

AChE

 

CaMK IIα

 

iNOS

 

体外研究
(In Vitro)

Bacoside A (8 μg/mL) 可在 LN229、U87MG 及 U251 胶质母细胞瘤细胞中诱导非凋亡、巨胞饮驱动的细胞死亡,而对正常 HaCaT 或 SVG 细胞无细胞毒性作用。
Bacoside A (8 μg/mL) 可诱导 LN229 和 U87MG 胶质母细胞瘤细胞中溶酶体前、小窝蛋白 1 阳性的巨胞饮体形成,进而驱动液体蓄积和细胞肿胀。
Bacoside A (8 μg/mL; 24 h) 可特异性增强 LN229、U87MG 和 U251 胶质母细胞瘤细胞中 CaMK2A 的 T286 磷酸化水平,但对正常 HaCaT 或 SVG 细胞无影响。
Bacoside A (8 μg/mL; 24 h) 可诱导 CaMK2A 磷酸化,该过程不依赖钙调蛋白和钙离子,但后续的细胞内钙释放是 LN229 和 U87MG 胶质母细胞瘤细胞发生巨胞饮作用、细胞骨架损伤和细胞毒性的必要条件。
Bacoside A (0.2-1.0 mg/mL; 3 h) 在浓度高达 0.4 mg/mL 时不会显著降低 N2a 神经母细胞瘤细胞的存活率,但在更高浓度下会降低细胞存活率;在 0.6 mg/mL 时细胞存活率仍保持在 100% 以上。
Bacoside A (0.4 mg/mL; 1 h) 可在受 H2O2 (0.42 mM; 3 h) 胁迫后的 N2a 神经母细胞瘤细胞中维持细胞核完整性,减少 ROS 生成,并恢复线粒体膜电位。
Bacoside A (0.4 mg/mL; 1 h) 可在受 H2O2 (0.42 mM; 3 h) 胁迫后的 N2a 神经母细胞瘤细胞中展现出抗凋亡活性,但其效果弱于单体成分 Bacoside A3 (MS-J35149)、Bacopaside II (MS-B54296) 和 Bacopasaponin C (MS-V45629)。

Cell Cytotoxicity Assay

Cell Line: LN229, U87MG, U251 (human glioblastoma cell lines); HaCaT (normal human epidermal keratinocytes), SVG (normal human subventricular radial glial progenitors)
Concentration: 2, 4, 6, 8 μg/mL (12 h); 8 μg/mL (12-24 h, 24-48 h, 24 h, 48 h)
Incubation Time: 12 h (2, 4, 6, 8 μg/mL); 12-24 h, 24-48 h, 24 h, 48 h (8 μg/mL)
Result: Induced phase-lucent macropinosome-like vacuoles in LN229, U87MG, and U251 glioblastoma cells by 12-24 h at 8 μg/mL, which fused to occupy the entire cell space, causing cellular hypertrophy, swelling, rounding, and necrotic morphology by 24-48 h.
Caused near-complete cell death in treated glioblastoma cultures, while normal HaCaT and SVG cells showed no morphological changes or cytotoxicity at 8 μg/mL.
Resulted in negative TUNEL assay for apoptotic DNA fragmentation in treated LN229 and U87MG cells, confirming non-apoptotic cell death.

Immunofluorescence

Cell Line: LN229, U87MG, U251 (human glioblastoma cell lines); HaCaT (normal human epidermal keratinocytes), SVG (normal human subventricular radial glial progenitors)
Concentration: 8 μg/mL
Incubation Time: 24 h
Result: Increased the ratio of phospho-CaMK2A (T286) to non-phospho CaMK2A significantly in LN229, U87MG, and U251 glioblastoma cells compared to untreated controls.
Caused no significant increase in phospho-CaMK2A levels in treated normal HaCaT or SVG cells.

Apoptosis Analysis

Cell Line: H2O2-stressed N2a neuroblastoma cells
Concentration: 0.4 mg/mL (post 3 h 0.42 mM H2O2 treatment)
Incubation Time: 1 h (post 3 h 0.42 mM H2O2 treatment)
Result: Reduced Annexin V-FITC green fluorescence intensity in H2O2-stressed N2a cells, indicating decreased phosphatidylserine exposure.
Showed insignificant red fluorescence via PI staining, indicating minimal necrotic cell death.
Was less effective at alleviating apoptosis compared to individual bacoside A components bacoside A3, bacopaside II, and bacopasaponin C.
体内研究
(In Vivo)

Bacoside A (10 mg/kg/天;灌胃;每日给药;21 天) 显著缓解吗啡诱导的大鼠脑组织氧化应激,可通过使抗氧化酶活性恢复正常、减轻脂质过氧化与蛋白质羰基化、恢复膜结合 ATP 酶功能;单独给药时对这些标志物无影响。
Bacoside A (5-20 mg/kg;腹腔注射;造模前 24 小时单次给药) 在雄性 Wistar 大鼠中对帕金森病诱导的氧化损伤和神经元变性呈剂量依赖性的保护作用,其中 20 mg/kg 剂量可完全消除 PD 诱导的旋转行为变化,并将多种病理标志物恢复至假手术组水平。
Bacoside A 对 N-Nitrosodiethylamine (MS-J31233) 诱导的大鼠肝细胞癌表现出化学预防功效。
Bacoside A 可在乳腺癌、前列腺癌、肺癌小鼠模型中发挥抗肿瘤发生功效。
Bacoside A 安全性良好,不会损伤学习记忆障碍小鼠模型的学习与记忆能力。

Animal Model: albino Wistar (adult male, 150-200 g, morphine-induced oxidative stress model)
Dosage: 10 mg/kg b.w./day
Administration: p.o.; daily; 21 days
Result: Restored superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities to near normal, with significant increases relative to morphine-only treated rats.
Normalized reduced glutathione (GSH) levels relative to morphine-only treated rats.
Significantly decreased basal, FeSO4-induced, ascorbate-induced, and H2O2-induced lipid peroxide levels relative to morphine-only treated rats.
Reduced protein carbonyl content to 2.09 n mole/mg protein, a significant decrease relative to morphine-only treated rats.
Restored Na+/K+-ATPase activity to 0.54±0.03 mmol of phosphorous liberated/min/mg protein, Ca2+-ATPase activity to 0.53 mmol of phosphorous liberated/min/mg protein, and Mg2+-ATPase activity to 0.64 mmol of phosphorous liberated/min/mg protein, all significant increases relative to morphine-only treated rats.
Caused no significant changes in antioxidant enzyme activities, GSH levels, lipid peroxide levels, protein carbonyl content, or membrane-bound ATPase activities relative to control rats when administered alone.
Animal Model: Wistar rats (male, 8-10 weeks old, 295-340 g; Parkinson's disease model induced by 6-hydroxydopamine injection)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: i.p.; single dose 24 hours pre-PD induction
Result: Reduced PD-induced elevated turning values in a dose-dependent manner; the 20 mg/kg dose completely eliminated the PD-induced increase in turning values.
Reversed PD-mediated suppression of serum CAT and GSH-Px activities in a dose-dependent manner; the 20 mg/kg dose effectively restored these enzyme activities to near sham levels.
Dose-dependently suppressed PD-induced elevated hippocampal AChE and iNOS activities; the 20 mg/kg dose reduced these activities to levels close to the sham group.
Dose-dependently reduced PD-induced elevated serum levels of IL-1β, IL-6, TNF-α, and NF-κB p65; the 20 mg/kg dose effectively reversed PD-mediated elevations of IL-1β and IL-6.
Dose-dependently reduced PD-induced elevated hippocampal levels of COX-2, p53, Bax, caspase-3, caspase-9, and cytochrome c; the 20 mg/kg dose reduced COX-2, p53, and cytochrome c levels to near sham group values.

化学信息

分子量 768.97
分子式 C41H68O13
CAS No. 11028-00-5
别名 假马齿苋皂素 A

储存&溶解度

溶解度信息
Methanol: Soluble
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础